Voyager Therapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Voyager Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $14.89. The average 1-year stock price forecast is 326.65% higher than the current stock price, while the lowest is $8.00 (+129.23%) and the highest is $25 (+616.33%).

Price Target: $14.89 (+326.65%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$8.00	$14.89	$12	$25
Change	+129.23%	+326.65%	+243.84%	+616.33%

Analyst Ratings

The average analyst rating for Voyager Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	12	12	12	11	11
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $25	Buy	Reiterates	$25	+616.33%	Jun 25, 2026
Phil Nadeau TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 18, 2026
Debjit Chattopadhyay Guggenheim	Guggenheim	Buy Maintains $22	Buy	Maintains	$22	+530.37%	Jun 2, 2026
Yun Zhong Wedbush	Wedbush	Buy Maintains $8	Buy	Maintains	$8	+129.23%	May 18, 2026
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Buy Reiterates $12	Buy	Reiterates	$12	+243.84%	May 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

43.53M

from 40.37M

7.82%

from 40.37M

Revenue Next Year

61.69M

from 43.53M

41.71%

from 43.53M

EPS This Year

-1.58

from -2.04

EPS Next Year

-1.58

from -1.58

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	37.42M	40.91M	250.01M	80.00M	40.37M	43.53M
Revenue Growth	-78.14%	9.33%	511.16%	-68.00%	-49.53%	7.82%
Gross Profit	-36.37M	-14.86M	157.84M	-44.59M	-91.90M	43.53M
Gross Margin	-97.21%	-36.32%	63.13%	-55.74%	-227.62%	100.00%
Operating Income	-73.62M	-45.84M	122.01M	-80.51M	-128.34M	-104.80M
Net Income	-71.20M	-46.41M	132.33M	-65.00M	-119.72M	-98.50M
EPS	-	-	-	-	-2.04	-1.58
Free Cash Flow	3.94M	7.25M	-3.01M	25.61M	-83.94M	-100.40M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	125.7M
Avg	43.5M
Low	9.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	211.2%
Avg	7.8%
Low	-77.7%

EPS Forecast

EPS	2026	2027	2028
High	-0.71
Avg	-1.58
Low	-1.96

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-